InflaRx provides update on Phase 3 trial for Vilobelimab in PG, halted due to futility; analysis on 54 patients revealed.
JENA, Germany - On December 30, 2025, InflaRx N.V. (Nasdaq: IFRX), a leading biopharmaceutical company specializing in anti-inflammatory treatments targeting the complement system, released various data analyses from the Phase 3 study for vilobelimab in pyoderma gangrenosum (PG). The study was halted earlier in the year following a recommendation from the Independent Data Monitoring Committee (IDMC) due to lack of efficacy. The analyses presented include the primary intent-to-treat analysis and multiple post-hoc analyses conducted on the 54 patients who were part of the trial at the time it was stopped prematurely.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments